Tonix Pharmaceuticals Hol... (TNXP)
20.38
4.10 (25.18%)
At close: Mar 18, 2025, 3:59 PM
18.08
-11.27%
Pre-market: Mar 19, 2025, 05:48 AM EDT
25.18% (1D)
| Bid | 17.88 |
| Market Cap | 113.93M |
| Revenue (ttm) | 1.02M |
| Net Income (ttm) | -12.17M |
| EPS (ttm) | -8039 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.02 |
| Analyst | Strong Buy |
| Ask | 18.29 |
| Volume | 2,503,427 |
| Avg. Volume (20D) | 1,600,886 |
| Open | 16.00 |
| Previous Close | 16.28 |
| Day's Range | 15.51 - 21.70 |
| 52-Week Range | 6.76 - 1184.00 |
| Beta | 2.24 |
About TNXP
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, auto...
Industry Biotechnology
Sector Healthcare
IPO Date May 10, 2012
Employees 103
Stock Exchange NASDAQ
Ticker Symbol TNXP
Website https://www.tonixpharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for TNXP stock is "Strong Buy." The 12-month stock price forecast is $1100, which is an increase of 5297.45% from the latest price.
Stock ForecastsEarnings Surprise
Tonix Pharmaceuticals has released their quartely earnings
on Mar 18, 2025:
Next Earnings Release
Tonix Pharmaceuticals Holding Corp. is scheduled to release its earnings on May 12, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+10.23%
Tonix Pharmaceutical shares are trading higher aft...
Unlock content with
Pro Subscription
1 month ago
-54.47%
Tonix Pharmaceuticals shares are trading lower after the company announced a 1-for-100 reverse stock split.
